Risk factors: Diabetes and cardiovascular risk: Insights from clinical trials

被引：0
|
作者：
Osório J.
机构：
来源：
Nature Reviews Cardiology | 2010年 / 7卷 / 5期
关键词：
D O I：
10.1038/nrcardio.2010.38
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：239 / 239
相关论文
共 50 条
  • [21] New insights into cardiovascular risk factors and outcomes
    Pantelis A. Sarafidis
    George L. Bakris
    Nature Reviews Nephrology, 2015, 11 : 70 - 72
  • [22] QT interval, cardiovascular risk factors and risk of death in diabetes
    Veglio, M
    Chinaglia, A
    Cavallo-Perin, P
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2004, 27 (02) : 175 - 181
  • [23] Risk Reduction Reporting in Cardiovascular Clinical Trials
    Iyengar, Rupa L.
    Esquitin, Ricardo
    Shah, Kshitij A.
    Razzouk, Louai
    Bashey, Sameer
    Aneja, Ashish
    Mathew, Verghese
    Farkouh, Michael E.
    CIRCULATION, 2010, 122 (21)
  • [24] Cardiovascular risk factors, change in risk factors over 7 years, and the risk of clinical diabetes mellitus type 2 - The Tromso study
    Jacobsen, BK
    Bonaa, KH
    Njolstad, I
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2002, 55 (07) : 647 - 653
  • [25] HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics
    Kjeldsen, Emilie Westerlin
    Thomassen, Jesper Qvist
    Frikke-Schmidt, Ruth
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2022, 1867 (01):
  • [26] HYPERTENSION CLINICAL and cardiovascular risk factors
    Mabuza, L. H.
    SA PHARMACEUTICAL JOURNAL, 2007, 74 (03) : 8 - 13
  • [27] Is the Evidence From Clinical Trials for Cardiovascular Risk or Harm for Glitazones Convincing?
    Mannucci, Edoardo
    Monami, Matteo
    CURRENT DIABETES REPORTS, 2009, 9 (05) : 342 - 347
  • [28] Cardiovascular risk factors. Insights from Framingham Heart Study
    O'Donnel, Christopher J.
    Elosua, Roberto
    REVISTA ESPANOLA DE CARDIOLOGIA, 2008, 61 (03): : 299 - 310
  • [29] Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?
    Edoardo Mannucci
    Matteo Monami
    Current Diabetes Reports, 2009, 9 : 342 - 347
  • [30] Bridging Cardiovascular Risk from Clinical Trials to Real Life Population
    Chain, A. S. Y.
    Vannoord, C.
    Dieleman, J. P.
    Danhoff, M.
    Sturkenboom, M. C. J. M.
    Della Pasqua, O.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S32 - S32
12345